Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
anti-HMW-MAA IgG4 antibody
- Development stage
- Preclinical
- Lead developer
- King's College London
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Anti-HMW-MAA IgG4 antibody is a recombinant monoclonal antibody of the IgG4 subclass directed against the High Molecular Weight Melanoma Associated Antigen (HMW-MAA), also known as Chondroitin Sulfate Proteoglycan 4 (CSPG4). Developed by researchers at King's College London and the Institute of Cancer Research, this antibody was engineered as part of a comparative study to evaluate the functional properties of different antibody classes (IgG1, IgG4, and IgE) in melanoma immunotherapy. HMW-MAA is a membrane-bound protein overexpressed in more than 90% of melanomas and is implicated in tumor cell proliferation, migration, and metastasis. The IgG4 variant was designed to engage specific Fc receptors on immune effector cells, such as monocytes, to induce antibody-dependent cell-mediated phagocytosis (ADCP) and cytotoxicity (ADCC). Preclinical studies in NOD/SCID mice indicated that while the IgG4 antibody showed activity, its IgE counterpart demonstrated superior anti-tumor efficacy.
- Other names
- anti-HMW-MAA IgG4anti-CSPG4 IgG4 antibodyanti-CSPG-4 IgG4 antibodyanti-CSPG 4 IgG4 antibody
02
Targets
CSPG4 (Chondroitin sulfate proteoglycan 4)FCGR1A (High affinity immunoglobulin gamma fc receptor I)FcγRIIa/FcγRIIb (Low affinity immunoglobulin gamma Fc region receptor II-a and II-b)FCGR3A (Low affinity immunoglobulin gamma Fc region receptor III-A)
Beyond the preview
Go deeper on anti-HMW-MAA IgG4 antibody.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on anti-HMW-MAA IgG4 antibody.